Welcome to our dedicated page for Intellia Therape news (Ticker: NTLA), a resource for investors and traders seeking the latest updates and insights on Intellia Therape stock.
Intellia Therapeutics, Inc. reports clinical, regulatory and financing developments as a clinical-stage biopharmaceutical company using CRISPR gene editing and other core technologies. Its recurring updates center on in vivo and ex vivo therapeutic approaches for genetically defined diseases, including lonvoguran ziclumeran, or lonvo-z, for hereditary angioedema and nexiguran ziclumeran, or nex-z, for ATTR amyloidosis with cardiomyopathy and polyneuropathy.
Company announcements also cover Phase 3 clinical data, FDA interactions, biologics license application activity, quarterly financial results, common stock offerings, equity incentive grants and investor conference participation. These updates reflect Intellia's progress from gene-editing research and clinical development toward regulatory and commercial planning for its lead programs.
Intellia Therapeutics (Nasdaq: NTLA) announced management will participate in three investor conferences in early March 2026, including TD Cowen (March 3), Leerink Global Healthcare (March 9) and Barclays Global Healthcare (March 10). The March 3 and March 9 fireside chats will be webcast live.
Webcasts and replays will be available on the company's Events and Presentations page at intelliatx.com; replays will remain available for approximately 90 days after each event.
Intellia Therapeutics (Nasdaq: NTLA) will host a conference call on February 26, 2026 at 8:00 a.m. ET to discuss fourth-quarter and full-year 2025 financial results and business updates.
Investors may join via webcast or teleconference; a replay will be available for approximately 90 days on the company’s Events page.
Intellia Therapeutics (Nasdaq: NTLA) announced inducement equity awards granted on February 1, 2026 under its 2024 Inducement Plan.
The company awarded time-based restricted stock units totaling 30,600 shares to six new employees, vesting one-third annually over three years, subject to continued service. Awards were approved by the compensation committee under Nasdaq Listing Rule 5635(c)(4).
Intellia Therapeutics (NASDAQ:NTLA) said the FDA has lifted the clinical hold on the MAGNITUDE-2 Phase 3 trial of nexiguran ziclumeran (nex-z) for hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN).
The company plans to resume patient enrollment and dosing, has aligned with FDA on certain study modifications including enhanced liver safety monitoring, and increased MAGNITUDE-2 target enrollment from ~50 to ~60 patients. Engagement with FDA remains ongoing for the related MAGNITUDE Phase 3 trial in transthyretin amyloidosis with cardiomyopathy (ATTR-CM); an update will follow after alignment on the path forward.
Intellia Therapeutics (NASDAQ:NTLA) will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on January 14, 2026 at 9:00 a.m. PT. A live webcast will be available on the company’s Events and Presentations page in the Investors & Media section at www.intelliatx.com. A replay of the webcast will be available on the website for approximately 30 days after the presentation.
Intellia Therapeutics (NASDAQ: NTLA) announced that on January 1, 2026 it awarded inducement grants to two new employees under its 2024 Inducement Plan.
The grants are time-based restricted stock units totaling 22,800 shares of common stock, with one-third vesting annually over three years and vesting subject to continued service. The 2024 Inducement Plan was adopted by the board in June 2024. The awards were approved by Intellia’s compensation committee as a material inducement to employment under Nasdaq Listing Rule 5635(c)(4).
Intellia Therapeutics (NASDAQ:NTLA) announced on December 1, 2025 that it granted inducement equity awards to three new employees under its 2024 Inducement Plan as material inducements to employment.
The awards are time-based restricted stock units totaling 12,600 shares, vesting in thirds on December 1, 2026, 2027, and 2028, and are subject to continued service through each vesting date. The grants were approved by the compensation committee and were made outside the company’s shareholder-approved equity incentive plans pursuant to Nasdaq Listing Rule 5635(c)(4).
Intellia Therapeutics (NASDAQ:NTLA) reported longer-term Phase 1 data for one-time IV nexiguran ziclumeran (nex-z) in ATTR amyloidosis with cardiomyopathy as of an Aug 23, 2025 data cut. Across 36 patients, a single dose produced rapid, deep and durable serum TTR reduction through three years (mean 87% reduction at 36 months; mean TTR 22.9 µg/mL).
At 24 months, markers showed stability or improvement (NT-proBNP 70%, hs-Troponin T 85%, 6MWT 69%, NYHA 81% stable/improved) and a post-hoc matched analysis showed lower all-cause mortality (3.9 vs 12.7 per 100 patient-years; HR 0.27; p=0.009). Safety findings were consistent with prior data (IRRs, transaminase elevations; liver enzymes ≤ Grade 2).
Intellia Therapeutics (NASDAQ: NTLA) presented pooled Phase 1/2 data for a one-time 50 mg IV dose of lonvoguran ziclumeran (lonvo-z) in hereditary angioedema (HAE) on Nov 8, 2025.
Key results: mean plasma kallikrein reduction of 89% at month 24; 31 of 32 patients (97%) were attack-free and long-term prophylaxis (LTP)-free at data cutoff (Aug 29, 2025); 24 of 32 (75%) were attack-free and LTP-free ≥7 months (up to 32 months). Of 11 Phase 2 patients dosed 50 mg, 10 were attack-free and LTP-free.
Safety: well-tolerated with up to three years follow-up, one resolved pulmonary embolism in a patient with risk factors, one transient Grade 2 AST elevation, and no new long-term risks identified. Phase 3 HAELO topline readout expected by mid-2026.
Intellia Therapeutics (NASDAQ:NTLA) reported Q3 2025 results and clinical updates on November 6, 2025. The company said the FDA placed a clinical hold on the MAGNITUDE and MAGNITUDE-2 Phase 3 trials of nex-z after rare Grade 4 liver transaminase elevations; more than 650 patients are enrolled in MAGNITUDE and 47 patients in MAGNITUDE-2. Intellia completed enrollment in the Phase 3 HAELO trial of lonvo-z and expects topline HAELO data by mid-2026, with a potential U.S. launch in 1H 2027. Cash, cash equivalents and marketable securities were $669.9M at September 30, 2025, and are expected to fund operations into mid-2027. Third-quarter net loss was $101.3M.